You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201391 - 201400 of 207725 results
  1. Naloxone Nasal Spray Development

    SBC: IMMUNEXCITE, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The introduction of therapeutic monoclonal antibodies (mAbs) in cancer has come of age with mAbs now approved for various cancer types including breast cancer. Unmodified mAbs tend to have moderate efficacy in eliminating metastatic tumors even when combined with chemotherapeutic agents. Drug/Toxin mAb conjugates may bring additional clinical benefit but are ex ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Field Deployable Vapor Intrusion Monitor

    SBC: EndoCole, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Colonoscopy is the preferred tool for colorectal cancer screening and polyp removal but the procedure carries a high financial cost. Minimizing the use of sedation/anesthesia and reducing the challenges associated withcolonoscope insertion would significantly reduce this cost. EndoCole proposes to develop a low-cost medical guide device that is inserted before ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a new approach to screening for language impairments

    SBC: InseRT            Topic: NCI

    Significance: Accurate targeting, guidance and monitoring of interventional therapy in the brain are critical for maximizing the effectiveness and safety during and following neurosurgical procedures. Magnetic resonance imaging (MRI) is a critical tool forplanning and guiding neurosurgical procedures. In most cases, the MRI is obtained during a pre-operative session; however, either brain shift, e ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Injectable microgel for soft tissue repair

    SBC: DAYSAI BIOPHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): BCL6 is the most commonly involved oncogene in B-cell lymphomas, and is expressed constitutively in a majority of patients with the two most frequent forms of lymphoma: the diffuse large B-cell lymphomas (DLBCL) and follicular lymphoma (FL). Many of these BCL6 positive tumors require the continued presence of BCL6 in order to maintain their survival. BCL6, a me ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. New drug VS-110 for treating inflammatory bowel diseases

    SBC: KENTUCKY IMAGING TECHNOLOGIES LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Colorectal cancer is the third most common form of cancer and the second leading cause of cancer-related death in the US. Yet, if polyps are detected and removed early, colorectal cancer is largely preventable. Althoughoptical colonoscopy (OC), the current gold standard, detects more than 90% of colorectal neoplasms; it is invasive and can be uncomfortable, inc ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Magnetic Flow Sorter for Pancreatic Islet Isolation

    SBC: APT THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Bone metastasis is common in patients with advanced breast, prostate, and lung cancers as these tumors have a remarkable ability to metastasize to bone. Two-thirds of patients with metastatic bone cancer experience severe pain which is usually described as dull in character, constant in presentation, and gradually increasing in intensity with time. Bone cancer ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. optimized Human Apyrase for Bone Cancer Pain Treatment

    SBC: CLARITRAC, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Each year 1.6 million US women undergo biopsy for breast cancer diagnosis. Fortunately fewer and fewer women suffer through open surgical biopsy but rather receive minimally invasive image-guided needle based biopsy. Ultrasound imaging guidance is the dominant modality for this intervention as it offers the greatest balance of safety, patient comfort, expedienc ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Blocking a novel cytokine signaling pathway for the treatment of rheumatoid arthr

    SBC: Axios Biosciences, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): This Small Business Innovation Research (SBIR) Phase I application is in response to Funding Opportunity Announcement PA-12-088. Tumor-stromal interactions are increasingly recognized as critical components of the progression of human neoplasias, including tumor invasion and metastasis. Utilizing a novel high- throughput screening approach developed by the appl ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Wireless Sensor Inserts for Combating Incontinence-Associated Dermatitis

    SBC: WELLSPRING BIOSCIENCES, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): The development of drugs that inhibit the K-Ras oncogene represents one of the greatest unmet needs in the treatment of human cancer. The Ras gene is the most frequently mutated oncogene in cancer, with a greater than 30% cumulative mutation frequency across all cancer types. Cancers with Ras mutations are aggressive and respond poorly to standard therapies. Pr ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. A Virtually Supervised Web-Based Home Exercise Technology for Older Adults

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The majority of multiple myeloma (MM) patients will initially respond to standard chemotherapy. However, eventually relapse of the disease, associated with a multi-drug resistant phenotype, contributes to poor clinicaloutcomes. Modulation Therapeutics is dedicated towards developing strategies for targeting cancers like MM that home or metastasize to the bone. ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government